K. Sakai

H. Watari, N. Sakuragi, M. Shimizu, 2003, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

Mismatch-repair-deficient metastatic pancreatic ductal adenocarcinoma with a germline PALB 2 mutation : unusual genetics , unusual clinical course

K. Nishio, T. Nakajima, T. Fujino, 2017 .

Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic EGFR-Mutated NSCLC: RELAY Japanese Subset

Y. Ohe, K. Kiura, K. Goto, 2021, JTO clinical and research reports.

A Pilot Proficiency Testing Study for Assessing Cancer Gene Panel using Patient Samples and Next-generation Sequencing in Japan

Y. Yatabe, Misa Fuchioka, K. Nishio, 2021 .

Adjuvant nivolumab for hepatocellular carcinoma (HCC) after surgical resection (SR) or radiofrequency ablation (RFA) (NIVOLVE): A phase 2 prospective multicenter single-arm trial and exploratory biomarker analysis.

M. Kudo, Y. Minami, K. Ueshima, 2021 .

Genetic Pro ﬁ ling of Non-Small Cell Lung Cancer at Development of Resistance to First- or Second-Generation EGFR-TKIs by CAPP-Seq Analysis of Circulating Tumor DNA

K. Goto, K. Nishio, Y. Nakanishi, 2019 .

Amplification MET ( PF-02341066 ) in Gastric Cancer Positive for Antitumor Action of the MET Tyrosine Kinase Inhibitor Crizotinib

K. Nishio, K. Yanagihara, I. Okamoto, 2013 .

Antitumor Action of the MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) in Gastric Cancer Positive for MET Amplification

K. Nishio, K. Yanagihara, I. Okamoto, 2012, Molecular Cancer Therapeutics.

Preclinical Development Antitumor Action of the MET Tyrosine Kinase Inhibitor Crizotinib ( PF-02341066 ) in Gastric Cancer Positive for MET Ampli fi cation

K. Nishio, K. Yanagihara, I. Okamoto, 2012 .

Serpina3n, Dominantly Expressed in Female Osteoblasts, Suppresses the Phenotypes of Differentiated Osteoblasts in Mice.

K. Nishio, K. Okada, K. Sakai, 2018, Endocrinology.

Targeted-sequence of normal urothelium and tumor of patients with non-muscle invasive bladder cancer

K. Nishio, N. Nonomura, M. Matsushita, 2022, Scientific Reports.

Patients with polyclonal hepatocellular carcinoma are at a high risk of early recurrence and have a poor recurrence-free survival period

M. D. De Velasco, K. Nishio, M. Sekimoto, 2021, Hepatology International.

Precision cancer genome testing needs proficiency testing involving all stakeholders

Y. Yatabe, Misa Fuchioka, K. Nishio, 2022, Scientific reports.

Activin signal promotes cancer progression and is involved in cachexia in a subset of pancreatic cancer.

Masato Terashima, Masatoshi Kudo, Masayuki Kitano, 2015, Cancer letters.

Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations

K. Goto, K. Nishio, Y. Nakanishi, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

A novel malignant peritoneal mesothelioma with STRN exon 2 and ALK exon 20 : a case report and literature review.

N. Matsumura, K. Nishio, S. Minamiguchi, 2021, The oncologist.

Contents Vol. 34, 2016

Y. Imai, M. Kudo, Y. Minami, 2016, Digestive Diseases.

Genetic profile of adult T‐cell leukemia/lymphoma in Okinawa: Association with prognosis, ethnicity, and HTLV‐1 strains

K. Karube, K. Nishio, H. Masuzaki, 2021, Cancer science.

Phase II Trial of the Combination of Alectinib with Bevacizumab in Alectinib Refractory ALK-Positive Nonsquamous Non-Small-Cell Lung Cancer (NLCTG1501)

K. Nishio, Daisuke Ishikawa, T. Sekiya, 2022, Cancers.

Combination bezafibrate and nivolumab treatment of patients with advanced non–small cell lung cancer

Young Hak Kim, T. Honjo, K. Nishio, 2022, Science Translational Medicine.

Combined effect of ALK and MEK inhibitors in EML4–ALK-positive non-small-cell lung cancer cells

P. Jänne, P. Janne, K. Azuma, 2012, British Journal of Cancer.

Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing

Masato Terashima, Shuta Tomida, Kazuko Sakai, 2015, PloS one.

The activation of SRC family kinases and focal adhesion kinase with the loss of the amplified, mutated EGFR gene contributes to the resistance to afatinib, erlotinib and osimertinib in human lung cancer cells

K. Nishio, M. Kuwano, M. Ono, 2017, Oncotarget.

HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

Kaoru Tanaka, K. Nishio, A. Tsuya, 2021, Clinical Cancer Research.

Intratumor heterogeneity and homologous recombination deficiency of high-grade serous ovarian cancer are associated with prognosis and molecular subtype and change in treatment course.

N. Matsumura, K. Nishio, M. Mandai, 2019, Gynecologic oncology.

HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer

K. Nishio, K. Nakagawa, Y. Komoike, 2018, Breast Cancer.

Transcriptional CCND1 expression as a predictor of poor response to neoadjuvant chemotherapy with trastuzumab in HER2-positive/ER-positive breast cancer

K. Nishio, T. Sudo, M. Tanioka, 2014, Breast Cancer Research and Treatment.

Longitudinal monitoring of somatic genetic alterations in circulating cell‐free DNA during treatment with epidermal growth factor receptor–tyrosine kinase inhibitors

K. Nishio, Y. Nakanishi, K. Azuma, 2019, Cancer.

Clinical characteristics of non-small cell lung cancer harboring mutations in exon 20 of EGFR or HER2

Kaoru Tanaka, K. Nishio, J. Tanizaki, 2018, Oncotarget.

Comprehensive Gene Mutation Profiling of Circulating Tumor DNA in Ovarian Cancer: Its Pathological and Prognostic Impact

K. Nishio, K. Sakai, K. Ino, 2020, Cancers.

Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment

T. Mitsudomi, S. Tomida, Kaoru Tanaka, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

An HER3-targeting antibody–drug conjugate incorporating a DNA topoisomerase I inhibitor U3-1402 conquers EGFR tyrosine kinase inhibitor-resistant NSCLC

K. Nishio, K. Nakagawa, Y. Chiba, 2018, Oncogene.

Context-Specific Efficacy of Apalutamide Therapy in Preclinical Models of Pten-Deficient Prostate Cancer

M. D. De Velasco, K. Nishio, K. Fujita, 2021, Cancers.

Sorafenib Inhibits the Hepatocyte Growth Factor–Mediated Epithelial Mesenchymal Transition in Hepatocellular Carcinoma

M. Kudo, N. Saijo, K. Nishio, 2011, Molecular Cancer Therapeutics.

FOXQ1 is overexpressed in colorectal cancer and enhances tumorigenicity and tumor growth.

Kaoru Tanaka, M. D. De Velasco, K. Nishio, 2010, Cancer research.

Mucosal microbiota and gene expression are associated with long-term remission after discontinuation of adalimumab in ulcerative colitis

H. Ogata, M. Kudo, H. Kashida, 2020, Scientific Reports.

Akt-dependent nuclear localization of Y-box-binding protein 1 in acquisition of malignant characteristics by human ovarian cancer cells

Y. Oda, H. Izumi, K. Kohno, 2007, Oncogene.

Multiple regulatory mechanisms of hepatocyte growth factor expression in malignant cells with a short poly(dA) sequence in the HGF gene promoter

K. Nishio, I. Okamoto, K. Nakagawa, 2014, Oncology letters.

Small cell lung cancer transformation and T790M mutation: complimentary roles in acquired resistance to kinase inhibitors in lung cancer

Y. Yatabe, T. Mitsudomi, S. Tomida, 2015, Scientific Reports.

Intra-tumor and Inter-tumor Heterogeneity in MET Exon 14 Skipping Mutations and Co-mutations in Pulmonary Pleomorphic Carcinomas.

J. Soh, T. Mitsudomi, K. Nishio, 2021, Clinical lung cancer.

Performance of Oncomine Fusion Transcript kit for formalin‐fixed, paraffin‐embedded lung cancer specimens

T. Ohira, N. Ikeda, T. Mitsudomi, 2019, Cancer science.

Simultaneous detection of lung fusions using a multiplex RT-PCR next generation sequencing-based approach: a multi-institutional research study

Roy R. L. Bastien, H. Feilotter, B. Tops, 2018, BMC Cancer.

Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A

Yusuke Nakamura, T. Mitsudomi, M. D. De Velasco, 2017, BMC Cancer.

MEK inhibitors against MET-amplified non-small cell lung cancer

Yusuke Nakamura, T. Mitsudomi, S. Tomida, 2016, International journal of oncology.

Functional Analyses of Mutations in Receptor Tyrosine Kinase Genes in Non–Small Cell Lung Cancer: Double-Edged Sword of DDR2

Yusuke Nakamura, T. Mitsudomi, S. Tomida, 2016, Clinical Cancer Research.

Clonal composition of human ovarian cancer based on copy number analysis reveals a reciprocal relation with oncogenic mutation status.

A. Roter, M. D. De Velasco, K. Nishio, 2017, Cancer letters.

Site-Specific and Targeted Therapy Based on Molecular Profiling by Next-Generation Sequencing for Cancer of Unknown Primary Site: A Nonrandomized Phase 2 Clinical Trial.

S. Tomida, K. Nishio, Y. Iwamoto, 2020, JAMA oncology.

Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling With Carboplatin and Paclitaxel for Patients With Cancer of Unknown Primary Site.

H. Mukai, Y. Ohashi, K. Nishio, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract 5169: Novel target molecules for treatment of cancer of unknown primary

K. Nishio, K. Nakagawa, T. Kurata, 2018, Tumor Biology.

Abstract 3993: A microarray-based gene expression analysis identified diagnostic biomarkers for unknown primary cancer

K. Nishio, Y. Koh, K. Nakagawa, 2014 .

Chronic nicotine exposure mediates resistance to EGFR-TKI in EGFR-mutated lung cancer via an EGFR signal.

S. Tomida, M. D. De Velasco, K. Nishio, 2015, Lung cancer.

O3-15-2CHRONIC NICOTINE EXPOSURE MEDIATES RESISTANCE TO EGFR-TKI IN EGFR-MUTATED LUNG CANCER VIA EGFR SIGNAL

S. Tomida, K. Nishio, K. Okamoto, 2014 .

Clinicopathological and genetic differences between low‐grade and high‐grade colorectal mucinous adenocarcinomas

K. Okuno, S. Tomida, M. D. De Velasco, 2015, Cancer.

A Microarray-Based Gene Expression Analysis to Identify Diagnostic Biomarkers for Unknown Primary Cancer

Yuichi Takiguchi, Hirofumi Mukai, Nobuyuki Yamamoto, 2013, PloS one.

A Novel Mass Spectrometry–Based Assay for Diagnosis of EML4-ALK–Positive Non–Small Cell Lung Cancer

K. Nishio, I. Okamoto, K. Takezawa, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Open-Label Phase II Study of the Efficacy of Nivolumab for Cancer of Unknown Primary.

K. Yonemori, Y. Iwamoto, J. Tanizaki, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical and immune profiling for cancer of unknown primary site

S. Tomida, K. Nishio, J. Tanizaki, 2019, Journal of Immunotherapy for Cancer.

FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib

Yusuke Nakamura, T. Mitsudomi, M. D. De Velasco, 2016, Cancer science.

Aberrant HER3 ligand heregulin-expressing head and neck squamous cell carcinoma is resistant to anti-EGFR antibody cetuximab, but not second-generation EGFR-TKI

Kaoru Tanaka, K. Nishio, K. Doi, 2019, Oncogenesis.

ACAGT-007a, an ERK MAPK Signaling Modulator, in Combination with AKT Signaling Inhibition Induces Apoptosis in KRAS Mutant Pancreatic Cancer T3M4 and MIA-Pa-Ca-2 Cells

T. Takasaki, K. Nishio, R. Sugiura, 2022, Cells.

aCGH Analysis of Predictive Biomarkers for Response to Bevacizumab plus Oxaliplatin- or Irinotecan-Based Chemotherapy in Patients with Metastatic Colorectal Cancer.

T. Yamanaka, E. Baba, N. Sugimoto, 2018, The oncologist.

Phase I safety and pharmacokinetic study of YM155, a potent selective survivin inhibitor, in combination with erlotinib in patients with EGFR TKI refractory advanced non-small cell lung cancer

Toshio Shimizu, K. Nishio, I. Okamoto, 2020, Cancer Chemotherapy and Pharmacology.

Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer.

K. Okuno, S. Tomida, M. D. De Velasco, 2015, International journal of oncology.

Prognostic implications of preoperative versus postoperative circulating tumor DNA in surgically resected lung cancer patients: a pilot study

J. Soh, T. Mitsudomi, K. Nishio, 2020, Translational lung cancer research.

The Japanese Society of Pathology Practical Guidelines on the handling of pathological tissue samples for cancer genomic medicine

A. Ochiai, Y. Kanai, E. Morii, 2021, Pathology international.

Clinical outcomes of thoracic radiotherapy for locally advanced NSCLC with EGFR mutations or EML4-ALK rearrangement.

Y. Nishimura, K. Nishio, I. Okamoto, 2012, Anticancer research.

Tumor volume determines the feasibility of cell‐free DNA sequencing for mutation detection in non‐small cell lung cancer

T. Ohira, Koichi Yoshida, M. Kakihana, 2016, Cancer science.

Serum Heparan Sulfate Concentration is Correlated with the Failure of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment in Patients with Lung Adenocarcinoma

T. Ohira, T. Yamanaka, N. Ikeda, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Targeted DNA and RNA sequencing of fine-needle biopsy FFPE specimens in patients with unresectable hepatocellular carcinoma treated with sorafenib

N. Izumi, K. Nishio, Y. Osaki, 2015, Oncotarget.

B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity

Kaoru Tanaka, K. Nishio, Y. Hasegawa, 2018, Clinical Cancer Research.

Development of On-Chip Multi-Imaging Flow Cytometry for Identification of Imaging Biomarkers of Clustered Circulating Tumor Cells

Kenji Yasuda, Yohei Miyagi, Mathias Girault, 2014, PloS one.

Changes in the gene mutation profiles of circulating tumor DNA detected using CAPP-Seq in neoadjuvant chemotherapy-treated advanced ovarian cancer

K. Nishio, K. Sakai, K. Ino, 2020, Oncology letters.

Liquid biopsy-based comprehensive gene mutation profiling for gynecological cancer using CAncer Personalized Profiling by deep Sequencing

K. Nishio, K. Sakai, K. Ino, 2019, Scientific Reports.

Sensitivities to various epidermal growth factor receptor‐tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor‐tyrosine kinase inhibitor?

Yusuke Nakamura, T. Mitsudomi, M. D. De Velasco, 2016, Cancer science.

Hypoxia induces resistance to ALK inhibitors in the H3122 non-small cell lung cancer cell line with an ALK rearrangement via epithelial-mesenchymal transition

K. Okuno, S. Tomida, M. D. De Velasco, 2014, International journal of oncology.

Abstract. Patients with non-small cell lung cancer (NSCLC) with echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) rearrangements

K. Okuno, S. Tomida, K. Nishio, 2014 .

Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib

P. Jänne, K. Nishio, I. Okamoto, 2016, Oncogene.

Detection of epidermal growth factor receptor T790M mutation in plasma DNA from patients refractory to epidermal growth factor receptor tyrosine kinase inhibitor

K. Nishio, M. Nishio, K. Sakai, 2013, Cancer science.

Inhibition of &bgr;-Catenin Enhances the Anticancer Effect of Irreversible EGFR-TKI in EGFR-Mutated Non–small-cell Lung Cancer with a T790M Mutation

S. Tomida, M. D. De Velasco, K. Nishio, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Significance of FGF9 gene in resistance to anti‐EGFR therapies targeting colorectal cancer: A subset of colorectal cancer patients with FGF9 upregulation may be resistant to anti‐EGFR therapies

S. Tomida, M. D. De Velasco, K. Nishio, 2017, Molecular carcinogenesis.

Impact of Serum Hepatocyte Growth Factor on Treatment Response to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non–Small Cell Lung Adenocarcinoma

T. Ohira, T. Yamanaka, N. Ikeda, 2010, Clinical Cancer Research.

Synergistic antitumor effects of S-1 with eribulin in vitro and in vivo for triple-negative breast cancer cell lines

M. D. De Velasco, K. Nishio, K. Sakai, 2014, SpringerPlus.

EGFR and HER2 signals play a salvage role in MEK1-mutated gastric cancer after MEK inhibition.

S. Tomida, M. D. De Velasco, K. Nishio, 2015, International journal of oncology.

Cell Lung Cancer Small − Positive Non − Resistance to ALK Inhibitors in EML 4-ALK Activation of HER Family Signaling as a Mechanism of Acquired

Kaoru Tanaka, K. Nishio, I. Okamoto, 2013 .

Clinical outcome for EML 4-ALK-positive patients with advanced non-small-cell lung cancer treated with fi rst-line platinum-based chemotherapy

K. Nishio, I. Okamoto, M. Takeda, 2012 .

Exploration of resistance mechanisms for epidermal growth factor receptor‐tyrosine kinase inhibitors based on plasma analysis by digital polymerase chain reaction and next‐generation sequencing

K. Goto, K. Nishio, Y. Nakanishi, 2018, Cancer science.

Heterogeneity in resistance mechanisms causes shorter duration of epidermal growth factor receptor kinase inhibitor treatment in lung cancer.

T. Mitsudomi, K. Nishio, K. Sakai, 2016, Lung cancer.

Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC

Yusuke Nakamura, S. Tomida, M. D. De Velasco, 2016, Molecular Cancer Therapeutics.

Heregulin expression and its clinical implication for patients with EGFR-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors

Kaoru Tanaka, K. Nishio, K. Azuma, 2019, Scientific Reports.

KRAS Inhibitor Resistance in MET-Amplified KRASG12C Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms

K. Nishio, J. Tanizaki, K. Nakagawa, 2021, Clinical Cancer Research.

Inter- and intra-tumor profiling of multi-regional colon cancer and metastasis.

K. Okuno, K. Nishio, K. Sakai, 2015, Biochemical and biophysical research communications.

Immunological Microenvironment Predicts the Survival of the Patients with Hepatocellular Carcinoma Treated with Anti-PD-1 Antibody

M. Kudo, Y. Minami, S. Hagiwara, 2021, Liver Cancer.

Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples

K. Nishio, K. Azuma, I. Okamoto, 2015, Oncotarget.

A Randomized Phase II Study Comparing Nivolumab with Carboplatin–Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L)

K. Nishio, K. Azuma, Y. Fukuda, 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.

High Incidence of C797S Mutation in Patients With Long Treatment History of EGFR Tyrosine Kinase Inhibitors Including Osimertinib

K. Sugio, K. Nishio, K. Nabeshima, 2021, JTO clinical and research reports.

Barcode sequencing identifies resistant mechanisms to epidermal growth factor receptor inhibitors in circulating tumor DNA of lung cancer patients

K. Nishio, M. Nishio, K. Sakai, 2019, Cancer science.

Detection of the T 790 M mutation of EGFR in plasma of advanced non – small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors ( West Japan oncology group 8014 LTR study )

T. Ohira, S. Bandoh, K. Nishio, 2016 .

act of Serum Hepatocyte Growth Factor on Treatment ponse to Epidermal Growth Factor Receptor Tyrosine ase Inhibitors in Patients with Non–Small Cell

T. Ohira, N. Ikeda, N. Saijo, 2010 .

Clinical outcome for EML4-ALK-positive patients with advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy.

K. Nishio, I. Okamoto, M. Takeda, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Predicting osimertinib‐treatment outcomes through EGFR mutant‐fraction monitoring in the circulating tumor DNA of EGFR T790M‐positive patients with non‐small cell lung cancer (WJOG8815L)

T. Ohira, K. Nishio, K. Azuma, 2020, Molecular oncology.

Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790M–positive non–small cell lung cancer: West Japan Oncology Group 8815L/LPS study

T. Ohira, K. Nishio, K. Azuma, 2020, Cancer.

Impact of coexisting gene mutations in EGFR-mutated non-small cell lung cancer before treatment on EGFR T790M mutation status after EGFR-TKIs.

Kaoru Tanaka, K. Nishio, K. Nakagawa, 2019, Lung cancer.

Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cancer negative for EGFR mutation and ALK fusion.

Kaoru Tanaka, K. Nishio, K. Nakagawa, 2019, Lung cancer.

Association of EGFR Exon 19 Deletion and EGFR-TKI Treatment Duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer Patients

K. Nishio, K. Azuma, S. Hattori, 2016, Scientific Reports.

Clinical outcome for EML4-ALK-positive patients with advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy.

K. Nishio, I. Okamoto, K. Nakagawa, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Impact of Serum HGF on Treatment Response to EGFR Tyrosine Kinase Inhibitors in Patients with Non-Small-Cell Lung Adenocarcinoma

T. Ohira, N. Ikeda, N. Saijo, 2010 .

Clinical significance of Akt2 in advanced pancreatic cancer treated with erlotinib.

Yusuke Nakamura, M. Kudo, M. D. De Velasco, 2017, International journal of oncology.

Homozygous deletion of the activin A receptor, type IB gene is associated with an aggressive cancer phenotype in pancreatic cancer

M. Kudo, S. Tomida, M. D. De Velasco, 2014, Molecular Cancer.

Successful human epidermal growth receptor 2-targeted therapy beyond disease progression for extramammary Paget’s disease

Toshio Shimizu, K. Nishio, N. Isogai, 2016, Investigational New Drugs.

Intestinal Microbiota and Gene Expression Reveal Similarity and Dissimilarity Between Immune-Mediated Colitis and Ulcerative Colitis

M. Kudo, K. Ueshima, T. Sakurai, 2021, Frontiers in Oncology.

Implementation of clinical sequencing for molecular profiling in patients with advanced cancer.

K. Nishio, K. Naoki, K. Nakagawa, 2021, Cancer biomarkers : section A of Disease markers.

New Era for Next-Generation Sequencing in Japan

Kazuko Sakai, Kazuhiko Nakagawa, Kazuya Fukuoka, 2019, Cancers.

Cytoplasmic p53 aggregates accumulated in p53-mutated cancer correlate with poor prognosis

K. Nishio, Yukio Fujiwara, M. Ueda, 2022, PNAS nexus.

Mutational activation of the epidermal growth factor receptor down‐regulates major histocompatibility complex class I expression via the extracellular signal‐regulated kinase in non–small cell lung cancer

K. Nishio, J. Tanizaki, K. Nakagawa, 2018, Cancer science.

Clinical application of amplicon-based next-generation sequencing to therapeutic decision making in lung cancer.

T. Mitsudomi, S. Tomida, K. Nishio, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Multivariate analysis for prognostic significance of histologic subtype, GST-pi, MDR-1, and p53 in stages II-IV ovarian cancer

H. Watari, N. Sakuragi, M. Shimizu, 2003, International Journal of Gynecologic Cancer.

Final results of adjuvant nivolumab for hepatocellular carcinoma (HCC) after surgical resection (SR) or radiofrequency ablation (RFA) (NIVOLVE): A phase 2 prospective multicenter single-arm trial and exploratory biomarker analysis.

M. Kudo, Y. Minami, K. Ueshima, 2022, Journal of Clinical Oncology.

Heterogeneity in congenital melanocytic nevi contributes to multicentric melanomagenesis.

K. Nishio, K. Sakai, T. Kawamura, 2020, Journal of dermatological science.

Docetaxel plus cisplatin in recurrent and/or metastatic non-squamous-cell head and neck cancer: a multicenter phase II trial

Kaoru Tanaka, K. Nishio, K. Sakai, 2021, Medical Oncology.

MEK Inhibitor for Gastric Cancer with MEK1 Gene Mutations

K. Okuno, S. Tomida, M. D. De Velasco, 2014, Molecular Cancer Therapeutics.

Cancer Biology and Signal Transduction MEK Inhibitor for Gastric Cancer with MEK 1 Gene Mutations

K. Okuno, S. Tomida, K. Nishio, 2014 .

Frequent PIK3CA mutations in eutopic endometrium of patients with ovarian clear cell carcinoma

N. Matsumura, K. Nishio, K. Sakai, 2021, bioRxiv.

Integrative analysis of gut microbiome and host transcriptomes reveals associations between treatment outcomes and immunotherapy‐induced colitis

H. Ogata, M. Kudo, T. Sakurai, 2021, Molecular oncology.

Lymph node metastatic melanoma from ungual melanoma: Identification of somatic mutations in KIT and LZTR1

A. Kawada, K. Nishio, N. Oiso, 2018, The Journal of dermatology.

Decreased expression of T‐cell‐associated immune markers predicts poor prognosis in patients with follicular lymphoma

K. Nishio, I. Matsumura, K. Sakai, 2021, Cancer science.

Refractory case of ulcerative colitis with idiopathic thrombocytopenic purpura successfully treated by Janus kinase inhibitor tofacitinib: A case report

M. Kudo, S. Hagiwara, Y. Komeda, 2020, World journal of clinical cases.

Impact of Tight Junction Protein ZO-1 and TWIST Expression on Postoperative Survival of Patients with Hepatocellular Carcinoma

M. Kudo, Y. Minami, S. Hagiwara, 2016, Digestive Diseases.

Human papillomavirus DNA and p16 expression in Japanese patients with oropharyngeal squamous cell carcinoma

Y. Nishimura, Kaoru Tanaka, K. Nishio, 2013, Cancer medicine.

Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer

K. Nishio, I. Okamoto, H. Yamaguchi, 2011, British Journal of Cancer.

Integrated analysis of whole genome exon array and array‐comparative genomic hybridization in gastric and colorectal cancer cells

K. Nishio, K. Yanagihara, M. Sekijima, 2012, Cancer science.

Uterine angioleiomyoma with disseminated intravascular coagulation: a case report

N. Matsumura, K. Nishio, K. Sakai, 2023, BMC Women's Health.

CAPP-seq analysis of circulating tumor DNA from patients with EGFR T790M–positive lung cancer after osimertinib

Kaoru Tanaka, K. Nishio, J. Tanizaki, 2021, International Journal of Clinical Oncology.

Determination of Somatic Mutations and Tumor Mutation Burden in Plasma by CAPP-Seq during Afatinib Treatment in NSCLC Patients Resistance to Osimertinib

K. Nishio, K. Azuma, T. Hoshino, 2020, Scientific Reports.

Association between Genetic and Immunological Background of Hepatocellular Carcinoma and Expression of Programmed Cell Death-1

M. Kudo, Y. Minami, S. Hagiwara, 2020, Liver Cancer.

A Case of Metastatic Malignant Breast Adenomyoepithelioma With a Codon-61 Mutation of HRAS.

K. Nishio, K. Nakagawa, M. Takeda, 2019, Clinical breast cancer.

Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification

I. Okamoto, J. Tanizaki, K. Nakagawa, 2011, British Journal of Cancer.

Dimerization and the signal transduction pathway of a smallin‐frame deletion in the epidermal growth factor receptor

N. Saijo, K. Nishio, T. Tamura, 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Patients with SMARCA4-deficient thoracic sarcoma and severe skeletal-related events.

K. Nishio, K. Kunimasa, F. Imamura, 2019, Lung cancer.

Successful long-term treatment of non–small cell lung cancer positive for RET rearrangement with pemetrexed

K. Nishio, K. Nakagawa, M. Takeda, 2019, OncoTargets and therapy.

Inter- and Intratumor Heterogeneity of EGFR Compound Mutations in Non-Small Cell Lung Cancers: Analysis of Five Cases.

J. Soh, T. Mitsudomi, K. Nishio, 2020, Clinical lung cancer.

Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells: FGFR2 as a potential target for salvage after lapatinib failure.

Kazuko Sakai, Taroh Satoh, Kazuhiko Nakagawa, 2011, Biochemical and biophysical research communications.

HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer

K. Nishio, T. Satoh, I. Okamoto, 2015, Oncotarget.

Performance of Ultra-Rapid Idylla™ EGFR Mutation Test in Non-Small-Cell Lung Cancer and Its Potential at Clinical Molecular Screening

T. Ohira, N. Ikeda, T. Mitsudomi, 2023, Cancers.

Durable response to EGFR tyrosine kinase inhibitors in a patient with non–small cell lung cancer harboring an EGFR kinase domain duplication

K. Nishio, C. Sato, K. Nakagawa, 2021, Thoracic cancer.

Slug Increases Sensitivity To Tubulin Binding Agents Via The Downregulation Of Beta III And IVa-Tubulin In Lung Cancer Cells

W. Nishio, N. Saijo, K. Nishio, 2012, ATS 2012.

Antitumor Activity of BIBF 1120, a Triple Angiokinase Inhibitor, and Use of VEGFR2+pTyr+ Peripheral Blood Leukocytes as a Pharmacodynamic Biomarker In Vivo

M. Kudo, N. Saijo, Kaoru Tanaka, 2010, Clinical Cancer Research.

Integrin-linked kinase pathway in heterogeneous pulmonary sarcomatoid carcinoma.

T. Mitsudomi, K. Nishio, T. Chikugo, 2021, Oncology letters.

A comparative study of curated contents by knowledge-based curation system in cancer clinical sequencing

Shinichiro Suzuki, Shigeki Shimizu, Kazuko Sakai, 2019, Scientific Reports.

Next-generation sequencing–based clinical testing for lung cancer in Japan

K. Nishio, K. Nakagawa, M. Takeda, 2017 .

Detection of the T790M mutation of EGFR in plasma of advanced non–small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study)

Kazuko Sakai, Tatsuo Ohira, Kazuhiko Nakagawa, 2016, Oncotarget.

Clinical, Pathological, and Molecular Features of Lung Adenocarcinomas with AXL Expression

T. Mitsudomi, K. Nishio, S. Shimizu, 2016, PloS one.

Myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN with RS-T) complicated by hyperleukocytosis and gene analysis in relation to leukocytosis

K. Nishio, T. Itoh, Takayuki Takahashi, 2019, Journal of clinical and experimental hematopathology : JCEH.

Clinical Application of the FoundationOne CDx Assay to Therapeutic Decision‐Making for Patients with Advanced Solid Tumors

T. Mitsudomi, H. Handa, Kaoru Tanaka, 2020, The oncologist.

Efficacy of Crizotinib After Entrectinib Resistance Due to MET Polysomy in ROS1-Rearranged NSCLC: A Case Report

K. Nishio, K. Nakagawa, K. Sakai, 2023, JTO clinical and research reports.

In-frame deletion in the EGF receptor alters kinase inhibition by gefitinib.

Kazuko Sakai, N. Saijo, H. Yokote, 2006, The Biochemical journal.

Exploration of resistance mechanisms for epidermal growth factor receptor‐tyrosine kinase inhibitors based on plasma analysis by digital polymerase chain reaction and next‐generation sequencing

K. Goto, K. Nishio, Y. Nakanishi, 2018, Cancer science.

Activation of ERK1/2 by MOS and TPL2 leads to dasatinib resistance in chronic myeloid leukaemia cells

K. Nishio, T. Takeda, S. Nishida, 2023, Cell proliferation.

Alternating Therapy With Osimertinib and Afatinib Blockades EGFR Secondary Mutation in EGFR-Mutant Lung Cancer: A Single-Arm Phase II Trial.

K. Nishio, K. Azuma, N. Yamamoto, 2023, Clinical lung cancer.

Association of EGFR Exon 19 Deletion and EGFR-TKI Treatment Duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer Patients

K. Nishio, S. Hattori, T. Kinoshita, 2022 .

Liquid biopsy-based comprehensive gene mutation profiling for gynecological cancer using CAncer Personalized Profiling by deep Sequencing

K. Nishio, K. Sakai, K. Ino, 2019, Scientific Reports.

Clinical practice guidance for next‐generation sequencing in cancer diagnosis and treatment (Edition 1.0)

Shingo Matsumoto, Daisuke Kotani, Chikashi Ishioka, 2018, Cancer science.

Heterogeneity of EGFR-mutant clones and PD-L1 highly expressing clones affects treatment efficacy of EGFR-TKI and PD-1 inhibitor.

K. Nishio, M. Inoue, K. Kunimasa, 2018, Annals of Oncology.

Transcriptome Profiling and Metagenomic Analysis Help to Elucidate Interactions in an Inflammation-Associated Cancer Mouse Model

M. D. De Velasco, K. Nishio, Y. Kura, 2021, Cancers.

Abstract. Patients with non-small cell lung cancer (NSCLC) with echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) rearrangements

K. Okuno, S. Tomida, K. Nishio, 2014 .

Low frequency of intracranial progression in advanced NSCLC patients treated with cancer immunotherapies

K. Kiura, K. Nishio, K. Kunimasa, 2023, International journal of cancer.

Phylloid hypomelanosis associated with a mosaic trisomy 13 in the 13q31.3‐qter region: atypical phylloid distribution and typical hypomelanosis

A. Kawada, K. Nishio, N. Oiso, 2017, Pigment cell & melanoma research.

Abstract 1568: A2aR inhibition enhances the antitumor activity of CTLA4 blockade in mouse Pten-deficient prostate cancer

K. Nishio, M. Velasco, Y. Kura, 2021, Immunology.

Impact of Smad4 and p53 mutations on the prognosis of patients with pancreatic ductal adenocarcinoma undergoing chemotherapy.

M. Kudo, Tomohiro Watanabe, M. Takenaka, 2023, International journal of clinical oncology.

Activation of HER Family Signaling as a Mechanism of Acquired Resistance to ALK Inhibitors in EML4-ALK–Positive Non–Small Cell Lung Cancer

Kaoru Tanaka, K. Nishio, I. Okamoto, 2012, Clinical Cancer Research.

Determination of Somatic Mutations and Tumor Mutation Burden in Plasma by CAPP-Seq during Afatinib Treatment in NSCLC Patients Resistance to Osimertinib

K. Nishio, K. Azuma, T. Hoshino, 2020, Scientific Reports.

Association of EGFR Exon 19 Deletion and EGFR-TKI Treatment Duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer Patients

K. Nishio, K. Azuma, S. Hattori, 2016, Scientific Reports.

Chronic nicotine exposure mediates resistance to EGFR-TKI in EGFR-mutated lung cancer via an EGFR signal.

S. Tomida, M. D. De Velasco, K. Nishio, 2015, Lung cancer.

Sorafenib Inhibits the Hepatocyte Growth Factor–Mediated Epithelial Mesenchymal Transition in Hepatocellular Carcinoma

M. Kudo, N. Saijo, K. Nishio, 2011, Molecular Cancer Therapeutics.

Association of EGFR Exon 19 Deletion and EGFR-TKI Treatment Duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer Patients

K. Nishio, K. Azuma, S. Hattori, 2016, Scientific Reports.

Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and response to PD-1 blockade

S. Tomida, J. Tanizaki, R. Hatae, 2024, The Journal of clinical investigation.

Downregulated expression of PBRM1 in sarcomatoid hepatocellular carcinoma

M. D. De Velasco, K. Sakai, Shogo Tanaka, 2024, Oncology letters.

TP53 and/or BRCA1 Mutations Based on CtDNA Analysis as Prognostic Biomarkers for Primary Triple-Negative Breast Cancer

K. Sakai, M. Kai, Mai Yamada, 2024, Cancers.